Xponance Inc. Cuts Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Xponance Inc. trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 8.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,745 shares of the medical research company’s stock after selling 644 shares during the quarter. Xponance Inc.’s holdings in Charles River Laboratories International were worth $1,595,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of CRL. Regency Capital Management Inc. DE purchased a new position in Charles River Laboratories International in the fourth quarter worth $3,703,000. WCM Investment Management LLC purchased a new position in Charles River Laboratories International in the fourth quarter worth $1,396,000. DekaBank Deutsche Girozentrale grew its holdings in Charles River Laboratories International by 98.6% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 14,094 shares of the medical research company’s stock worth $3,333,000 after purchasing an additional 6,997 shares during the last quarter. AMG National Trust Bank purchased a new position in Charles River Laboratories International in the third quarter worth $1,119,000. Finally, DAVENPORT & Co LLC purchased a new position in Charles River Laboratories International in the fourth quarter worth $1,904,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CRL has been the topic of several analyst reports. Guggenheim lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Citigroup lifted their price target on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the stock a “neutral” rating in a report on Thursday, February 15th. UBS Group lifted their price objective on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a research note on Thursday, February 15th. Argus lifted their price objective on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. Finally, TheStreet upgraded shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $253.23.

Insider Transactions at Charles River Laboratories International

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the transaction, the executive vice president now directly owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the transaction, the executive vice president now directly owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP William D. Barbo sold 4,050 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the transaction, the vice president now owns 22,879 shares in the company, valued at $5,685,431.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,932 shares of company stock worth $3,693,663. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $239.98 on Wednesday. The firm has a 50 day simple moving average of $254.27 and a 200-day simple moving average of $222.23. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16. The stock has a market cap of $12.36 billion, a price-to-earnings ratio of 26.06, a price-to-earnings-growth ratio of 1.78 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $991.25 million. During the same quarter in the prior year, the company posted $2.98 EPS. The business’s revenue for the quarter was down 7.9% on a year-over-year basis. On average, analysts expect that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).